BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...
BioCentury | Jan 19, 2009
Finance

JPMorgan effect

JPMorgan effect Company Day chg Wk chg 1/16 cls ZymoGenetics (NASDAQ:ZGEN) -0.2% 50.5% $4.35 Illumina (NASDAQ:ILMN) 3.8% 29.4% $30.33 Human Genome (NASDAQ:HGSI) -6.8% 28.7% $2.42 CV Therapeutics (NASDAQ:CVTX) 1.9% 20.2% $10.83 Momenta (NASDAQ:MNTA) 5.8% 13.5%...
Items per page:
1 - 2 of 2